Urinary podocyte markers of disease activity, therapeutic efficacy, and long-term outcomes in acute and chronic kidney diseases
Clinical and Experimental Nephrology · 2024-06 · 28 (6) · 496-504
DOI: 10.1007/s10157-024-02465-y ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical and Experimental Nephrology, online erschienen am 25.02.2024. Verfasst von Akihiro Fukuda und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Metabolism, Rheumatology and Nephrology, Faculty of Medicine, Oita University, 1-1 Idaigaoka, Hasama-Machi, Yufu City, O…. Hauptthemen laut MEDLINE: Podocytes, Biomarkers. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Mitsubishi Tanabe Pharma Corporation, JSPS KAKENHI, Japan Foundation for Applied Enzynology.
Abstract (Originalsprache)
A critical degree of podocyte depletion causes glomerulosclerosis, and persistent podocyte loss in glomerular diseases drives the progression to end-stage kidney disease. The extent of podocyte injury at a point in time can be histologically assessed by measuring podocyte number, size, and density (“Biopsy podometrics”). However, repeated invasive renal biopsies are associated with increased risk and cost. A noninvasive method for assessing podocyte injury and depletion is required. Albuminuria and proteinuria do not always correlate with disease activity. Podocytes are located on the urinary space side of the glomerular basement membrane, and as they undergo stress or detach, their products can be identified in urine. This raises the possibility that urinary podocyte products can serve as clinically useful markers for monitoring glomerular disease activity and progression (“Urinary podometrics”). We previously reported that urinary sediment podocyte mRNA reflects disease activity in both animal models and human glomerular diseases. This includes diabetes and hypertension which together account for 60% of new-onset dialysis induction patients. Improving approaches to preventing progression is an urgent priority for the renal community. Sufficient evidence now exists to indicate that monitoring urinary podocyte markers could serve as a useful adjunctive strategy for determining the level of current disease activity and response to therapy in progressive glomerular diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, Metabolism, Rheumatology and Nephrology, Faculty of Medicine, Oita University, 1-1 Idaigaoka, Hasama-Machi, Yufu City, Oita, 879-5593, Japan. akifukuda@oita-u.ac.jp.
- Division of Nephrology, Department of Internal Medicine, National Health Insurance Takachiho Town Hospital, Takachiho, Miyazaki, Japan.
- Department of Endocrinology, Metabolism, Rheumatology and Nephrology, Faculty of Medicine, Oita University, 1-1 Idaigaoka, Hasama-Machi, Yufu City, Oita, 879-5593, Japan.
- Department of Medical Environment Innovation, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.
- Division of Nephrology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
Förderung
- Mitsubishi Tanabe Pharma Corporation
- JSPS KAKENHI
- Japan Foundation for Applied Enzynology
- Dainippon Sumitomo Pharma
- Takeda Science Foundation
- Oita University
Zitieren
APA
Fukuda, A., Sato, Y., Shibata, H., Fujimoto, S., & Wiggins, R. C. (2024). Urinary podocyte markers of disease activity, therapeutic efficacy, and long-term outcomes in acute and chronic kidney diseases. Clinical and Experimental Nephrology, 28(6), 496-504. https://doi.org/10.1007/s10157-024-02465-y
Vancouver
Fukuda A, Sato Y, Shibata H, Fujimoto S, Wiggins RC. Urinary podocyte markers of disease activity, therapeutic efficacy, and long-term outcomes in acute and chronic kidney diseases. Clinical and Experimental Nephrology. 2024;28(6):496-504. doi:10.1007/s10157-024-02465-y
BibTeX
@article{Fukuda2024,
author = {Fukuda, Akihiro and Sato, Yuji and Shibata, Hirotaka and Fujimoto, Shouichi and Wiggins, Roger C},
title = {Urinary podocyte markers of disease activity, therapeutic efficacy, and long-term outcomes in acute and chronic kidney diseases},
journal = {Clinical and Experimental Nephrology},
year = {2024},
volume = {28},
number = {6},
pages = {496--504},
doi = {10.1007/s10157-024-02465-y}
}
EUVIMED